COMPARISON OF IMMUNOCHROMATOGRAPHIC TEST NEGATIVE HEPATITIS B VIRUS AND HEPATITIS C VIRUS BLOOD DONATIONS WITH ELISA IN PUBLIC AND PRIVATE BLOOD BANKS OF LAHORE - PAKISTAN

Main Article Content

Aftab Khan
Obaid Ullah
Israr Ahmad
Ambreen
Farkhinda Ghafoor

Abstract

Objectives: To determine the frequency of immunochromatographic test for false negative HBV and HCV testing among healthy blood donors in Lahore - Pakistan.


Methodology: This was 18 months cross sectional pilot study, conducted in private and public blood banks of city Lahore. After taking formal consent from head of selected Hospital and in charge blood bank/ donors, blood bags screened as HBs Ag and Anti HCV negative by immune-chromatographic (ICT) method, 3-5 ml blood was transferred to coded tube and later transferred to ex-PHRC research Centre NHRC Lahore, where plasma was separated through centrifugation and stored at -40/-20C. Collected samples from this Centre sent to ex-PHRC Research Centre Khyber Medical College Peshawar in cold chain for ELISA testing.


Results: Study found that among 385 HBs Ag and anti HCV ICT negative Labeled blood bags 0.8 % was positive for HBs Ag and 2.1% blood bags was positive for anti HCV antibody on ELISA testing. Frequency of AB –ive and A-ive blood bags availability were very rare, 1 % for both types. False negative testing rate of blood bags was comparatively high in public sectors hospitals (1 % for HBs Ag and 3.2% for anti HCV) than private sector hospitals (0.5% for HBs Ag and 1% for anti HCV. False negative ICT testing rate was observed high among blood group B +ive (0.8% for HBV and 4.1% for HCV) than all other blood groups.


Conclusion: Study found that 0.8% blood bags were screened falsely negative by immuno-chromatographic method (ICT) for HBs Ag and 2.1% for anti HCV.

Article Details

How to Cite
1.
Khan A, Obaid Ullah, Israr Ahmad, Ambreen, Farkhinda Ghafoor. COMPARISON OF IMMUNOCHROMATOGRAPHIC TEST NEGATIVE HEPATITIS B VIRUS AND HEPATITIS C VIRUS BLOOD DONATIONS WITH ELISA IN PUBLIC AND PRIVATE BLOOD BANKS OF LAHORE - PAKISTAN. J Postgrad Med Inst [Internet]. 2023 Aug. 27 [cited 2024 Jun. 13];37(3):186-90. Available from: https://jpmi.org.pk/index.php/jpmi/article/view/3200
Section
Original Article

References

Acar A, Kemahli S, Altunay H, Kosan E, Oncul O, Gorenek L, Cavuslu S, et al. HBV, HCV and HIV sero-prevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies? Braz J Infect Dis. 2010;14(1):41-46

Busch MP, Stramer SL, Kleinman SH. Evolving applications of nucleic acid amplification assays for prevention of viral transmission by blood components and derivatives. In: Garratty G, ed. Applications of molecular biology to blood transfusion medicine. Bethesda: American Association of Blood Banks. 1997;1:123-76.

Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685-90.

Kleinman SH, Busch MP, Korelitz JJ, Schreiber GB. The incidence window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev. 1997;11:155-72.

Rahman M, Khan SA, Lodhi Y. Unconfirmed reactive screening tests and their impact on donor management. Pak J Med Sci. 2008;24(4):517-9.

Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion- transmitted infections. J Transl Med. 2007; 6; 5:25.

Alter HJ, Houghton M. Clinical Medical Research Award. Hepatitis C virus and eliminating post transfusion hepatitis. Nat Med. 2000; 6(10):1082-6.

Heper Y. Transfüzyonda Mikrobiyolojik Tarama Testleri. Antibiyotik ve Kemoterapi Dergisi. 2007; 21(Ek 2):146-52.

Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: Prevalence and risk factors. Int J Infect Dis. 2009;13:9-19.

Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J. Gastroenterol.2009;15:5647-53.

PMRC National Survey on Prevalence of Hepatitis B & C in General Population of Pakistan (2007-2009). Pakistan Medical Research Council, Shahrah-e-Jamhuriat, Sector G-5/2, Islamabad.

Pillonel J, Saura C, Courouce AM. Prevalence of HIV, HTLV, and hepatitis B and C viruses in blood donors in France, 1992–1996. Transfus Clin Biol. 1998;5:305-12.

Behzad-Behbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB. Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res. 2006;123(1):37.

Rahman M, Khan SA, Lodhi Y. Unconfirmed reactive screening tests and their impact on donor management. Pak J Med Sci. 2008;24(4):517-9.

Behzad-Behbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB, Torab A, Moaddeb A. Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res 2006; 123:37–42.

Seo DH, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion (Paris) 2011;51:1840–6.

Dhawan HK, Marwaha N, Sharma RR, Chawla Y, Thakral B, Saluja K, et al. Anti-HBc screening in Indian blood donors: Still an unresolved issue. World J Gastroenterol Wjg 2008;14:5327-30. DOI: 10.3748/wjg.14.5327

Bjoerkvoll B, Viet L, Ol HS, Lan NTN, Sothy S, Hoel H, et al. Screening test accuracy among potential blood donors of HBsAg, anti-HBc and anti-HCV to detect hepatitis B and C virus infection in rural Cambodia and Vietnam. Southeast. Asian J Trop Med Public Health.2010;41:1127–35.

Khalid M, Aslam N, Siyar M, Ahmad R. Distribution of ABO and Rh (D) blood groups among blood donors in district Mardan, Pakistan. J Saidu Med Col. 2013;3(2).318-22. DOI: 10.52206/ jsmc.2013.3.2.318-322

Busch MP, Watanabe KK, Smith JW, Hermansen SW, Thomson RA. False negative testing errors in routine viral marker screening of blood donors. Transfusion. 2000;40(5):585-9.